SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency

Saki Takahashi; Michael J Peluso; Jill Hakim; Keirstinne Turcios; Owen Janson; Isobel Routledge; Michael Paul Busch; Rebecca Hoh; Viva Tai; J. Daniel Kelly; Jeffrey N. Martin; Steven G Deeks; Timothy J. Henrich; Bryan Greenhouse; Isabel Rodriguez-Barraquer.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21263139

Documentos relacionados

  1. SARS-CoV-2 Serology Across Scales: A Framework for Unbiased Estimation of Cumulative Incidence Incorporating Antibody Kinetics and Epidemic Recency.
  2. SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency.
  3. Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies.
  4. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
  5. Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity.
  6. Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2.
  7. Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections.
  8. The evolution and interpretation of seroprevalence of SARS-CoV-2 antibodies among South African blood donors from the Beta to Omicron variant-driven waves.
  9. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
  10. A simulation-based method to inform serosurvey design for estimating the force of infection using existing blood samples.